Elsevier

Psychiatry Research

Volume 58, Issue 3, 16 October 1995, Pages 191-201
Psychiatry Research

Article
Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study

https://doi.org/10.1016/0165-1781(95)02601-RGet rights and content

Abstract

The effect of month-long naltrexone (NTX) treatment at a daily oral dose of 0.5 mg/kg/day was contrasted with placebo (PLC) in a double-blind study with conjoint clinical and biochemical evaluations of therapeutic effects. Modest clinical benefits were achieved with both PLC and NTX, with marginally better overall results following NTX, and degree of improvement appeared to be related to plasma chemical profiles. Massively elevated levels of β-endorphin were observed in all children with assays using C-terminal antibody but not with an N-terminal antibody assay. In addition, 70% of the children exhibited abnormally low levels of adrenocorticotropic hormone, and smaller subsets exhibited elevated norepinephrine (60%), arginine-vasopressin (50%), and serotonin (20%). The best clinical responders exhibited the clearest normalization of the elevated plasma chemistries, especially in C-terminal-β-endorphin and serotonin. There was some evidence of therapeutic carry-over effects in both clinical and biochemical measures in those children who received NTX before PLC. The results suggest that NTX only benefits a subgroup of autistic children, who may be identified by the presence of certain plasma abnormalities. These results suggest a possible linkage between abnormal plasma chemistries, especially those related to the pro-opiomelanocortin system, and autistic symptoms.

References (40)

  • C. Barthélémy et al.

    The Behavioral Summarized Evaluation: validity and reliability of a scale for the assessment of autistic behaviors

    J Autism Dev Disord

    (1990)
  • M. Campbell et al.

    Naltrexone in autistic children: a double-blind and placebo-controlled study

    Psychopharmacol Bull

    (1990)
  • M. Campbell et al.

    Naltrexone in infantile autism

    Psychopharmacol Bull

    (1988)
  • M. Da Prada et al.

    Radioenzymatic assay of plasma and urinary catecholamines in man and various animal species: physiological and pharmacological applications

  • S. Deutsch

    Rationale for the administration of opiate antagonists in treating infantile autism

    Am J Ment Defic

    (1986)
  • B. Fish

    Children's Psychiatric Rating Scale

    Psychopharmacol Bull

    (1985)
  • C. Gillberg et al.

    Endorphin activity in childhood psychosis: spinal levels of 24 cases

    Arch Gen Psychiatry

    (1985)
  • C.H. Goyette et al.

    Normative data on revised Conners parent and teacher rating scales

    J Abnorm Child Psychol

    (1978)
  • R. Guillemin et al.

    Radioimmunoassays for alpha-endorphin and beta-endorpnin

    Biochem Biophys Commun

    (1977)
  • B.H. Herman

    Effects of opioid receptor antagonists in the treatment of autism and self-injurious behavior

  • Cited by (105)

    • The aetiology of social deficits within mental health disorders: The role of the immune system and endogenous opioids

      2020, Brain, Behavior, and Immunity - Health
      Citation Excerpt :

      They noted that the “behavioural change was also accompanied by an increase of T-helper-inducers and decrease in T-cytotoxic-suppressor, resulting in a normalization of the CD4/CD8 ratio” (p. 351). Other research looking at the effect of Naltrexone on ASD also shows some improvement (Bouvard et al., 1995; Campbell et al., 1993; Kolmen et al., 1995), especially with self-injurious behaviour (Eichaar et al., 2006; Sandman and Kemp, 2011) but only in a subgroup of those with ASD (Roy et al., 2015). Given the MOR-Balance model of ASD proposed by Pellissier et al. (2018), this subgroup may be the one with excessive MOR activity, compared to others with ASD who have insufficient MOR activity or some other biochemical cause of their symptoms.

    • Reconciling cognitive and affective neuroscience perspectives on the brain basis of emotional experience

      2017, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Aside from human self-reports already noted, which are generally consistent with the above thesis (Panksepp, 1985), another relevant approach would be to test novel psychiatric predictions. That has been achieved to a modest extent for childhood autism (Bouvard et al., 1995) and robustly in the treatment of depression (for reviews, see Panksepp, 2015a; Panksepp et al., 2014). #2.

    • The Neurobiology of Social Affiliation and Pair Bonding

      2017, Hormones, Brain and Behavior: Third Edition
    View all citing articles on Scopus
    View full text